Literature DB >> 22918866

Desulfurization of mucin by Pseudomonas aeruginosa: influence of sulfate in the lungs of cystic fibrosis patients.

Camilla V Robinson1, Mark R Elkins2, Katarzyna M Bialkowski3, David J Thornton1, Michael A Kertesz3,1.   

Abstract

Pseudomonas aeruginosa is a common cause of chronic respiratory infection in cystic fibrosis (CF) patients. Infection is established within the lung epithelial mucus layer through adhesion to mucins. Terminal residues on mucin oligosaccharide chains are highly sulfated and sialylated, which increases their resistance to degradation by bacterial enzymes. However, a number of microbes, including P. aeruginosa, display mucin sulfatase activity. Using ion chromatography, the levels of sulfation on different respiratory mucins and the availability of inorganic sulfate to pathogens in sputum from CF patients were quantified. The ability of clinical isolates of P. aeruginosa to desulfate mucin was tested by providing mucin as a sole sulfur source for growth. All tested P. aeruginosa strains isolated from the lungs of CF patients were able to use human respiratory mucin as a source of sulfur for growth, whereas other non-clinical species of the genus Pseudomonas were not. However, measured levels of inorganic sulfate in sputum from CF patients suggested that bacteria resident in the lung have sufficient inorganic sulfate for growth and are unlikely to require access to mucin sulfur as a sulfur source during chronic infection. This was confirmed when expression of sulfate-repressed P. aeruginosa genes atsK and msuE was found to be repressed in the sputum of CF patients, which was detected by using quantitative RT-PCR. These results indicate that sulfate starvation is unlikely to occur in pathogens residing in the sputum of CF patients and, therefore, mucin desulfation may have an alternative purpose in the association between P. aeruginosa and the airways of CF patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22918866     DOI: 10.1099/jmm.0.047167-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  16 in total

1.  Genome-Wide Survey of Pseudomonas aeruginosa PA14 Reveals a Role for the Glyoxylate Pathway and Extracellular Proteases in the Utilization of Mucin.

Authors:  Jeffrey M Flynn; Chi Phan; Ryan C Hunter
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

2.  The impact of Lactococcus lactis (probiotic nasal rinse) co-culture on growth of patient-derived strains of Pseudomonas aeruginosa.

Authors:  Do-Yeon Cho; Daniel Skinner; Dong Jin Lim; John G Mclemore; Connor G Koch; Shaoyan Zhang; William E Swords; Ryan Hunter; David K Crossman; Michael R Crowley; Jessica W Grayson; Steven M Rowe; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2020-01-10       Impact factor: 3.858

Review 3.  Novel antimicrobial development using genome-scale metabolic model of Gram-negative pathogens: a review.

Authors:  Wan Yean Chung; Yan Zhu; Mohd Hafidz Mahamad Maifiah; Naveen Kumar Hawala Shivashekaregowda; Eng Hwa Wong; Nusaibah Abdul Rahim
Journal:  J Antibiot (Tokyo)       Date:  2020-09-08       Impact factor: 2.649

4.  Highly sialylated mucin-type glycopeptide from porcine intestinal mucosa after heparin extraction: O-glycan profiling and immunological activity evaluation.

Authors:  Xin Zhang; Chen Wang; Qing Han; Xuan Chen; Guoyun Li; Guangli Yu
Journal:  Glycoconj J       Date:  2021-09-04       Impact factor: 2.916

5.  Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence.

Authors:  Bethany D Batson; Bryan T Zorn; Giorgia Radicioni; Stephanie S Livengood; Tadahiro Kumagai; Hong Dang; Agathe Ceppe; Phillip W Clapp; Michael Tunney; J Stuart Elborn; Noel G McElvaney; Marianne S Muhlebach; Richard C Boucher; Michael Tiemeyer; Matthew C Wolfgang; Mehmet Kesimer
Journal:  Am J Respir Cell Mol Biol       Date:  2022-08       Impact factor: 7.748

6.  Citizen-science based study of the oral microbiome in Cystic fibrosis and matched controls reveals major differences in diversity and abundance of bacterial and fungal species.

Authors:  Jesse R Willis; Ester Saus; Susana Iraola-Guzmán; Elena Cabello-Yeves; Ewa Ksiezopolska; Luca Cozzuto; Luis A Bejarano; Nuria Andreu-Somavilla; Miriam Alloza-Trabado; Andrea Blanco; Anna Puig-Sola; Elisabetta Broglio; Carlo Carolis; Julia Ponomarenko; Jochen Hecht; Toni Gabaldón
Journal:  J Oral Microbiol       Date:  2021-05-17       Impact factor: 5.474

7.  The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.

Authors:  Laura K Green; Mathew A Storey; Elsie M Williams; Adam V Patterson; Jeff B Smaill; Janine N Copp; David F Ackerley
Journal:  Cancers (Basel)       Date:  2013-08-08       Impact factor: 6.639

Review 8.  Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease.

Authors:  Michael C McKelvey; Ryan Brown; Sinéad Ryan; Marcus A Mall; Sinéad Weldon; Clifford C Taggart
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

9.  Biogeochemical forces shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung.

Authors:  Robert A Quinn; Yan Wei Lim; Heather Maughan; Douglas Conrad; Forest Rohwer; Katrine L Whiteson
Journal:  MBio       Date:  2014-03-18       Impact factor: 7.867

10.  Evidence and Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease.

Authors:  Jeffrey M Flynn; David Niccum; Jordan M Dunitz; Ryan C Hunter
Journal:  PLoS Pathog       Date:  2016-08-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.